{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:14:20Z","timestamp":1790255660686,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["214151"],"award-info":[{"award-number":["214151"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int Forum Allergy Rhinol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trial data demonstrate that mepolizumab, a humanized anti\u2010interleukin 5 monoclonal antibody, is effective for patients with severe asthma and comorbid chronic rhinosinusitis (CRS) with nasal polyps. This real\u2010world, retrospective cohort study investigated mepolizumab for US patients with severe asthma and CRS with\/without sinus surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>IQVIA PharMetrics Plus claims data from baseline and follow\u2010up (12 months before and after mepolizumab initiation) were used to analyze three patient cohorts: cohort 1 (severe asthma only); cohort 2 (severe asthma\u00a0+\u00a0comorbid CRS without sinus surgery); and cohort 3 (severe asthma+comorbid CRS+sinus surgery), allowing for cross\u2010cohort comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis included 495, 370, and 85 patients in cohort 1, cohort 2, and cohort 3, respectively. Systemic and oral corticosteroid use was lower for all cohorts after mepolizumab initiation. In cohort 3, asthma rescue inhaler and antibiotic use were lower during follow\u2010up than baseline. Asthma exacerbations were reduced by 28% to 44% comparing follow\u2010up versus baseline, with the largest reduction in cohort 3 (ratio of incidence rate ratio [RR] vs cohort 1: 0.76;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.036). Reductions in oral corticosteroid claims were greater following mepolizumab initiation for cohort 3 versus cohort 1 (RR, 0.72;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.011) and cohort 2 (RR, 0.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.01). In cohorts 1 through 3, outpatient and emergency department visits were reduced by 1 to 2 and 0.4 to 0.6 visits annually, asthma\u2010related and asthma exacerbation\u2013related total costs were reduced by $387 to $2580 USD, and medical costs were reduced by $383 to $2438 USD during follow\u2010up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consistent with trial data, mepolizumab use in real\u2010world practice shows benefits across comorbid patient cohorts with more a pronounced impact in those with severe asthma+comorbid CRS\u00a0+\u00a0sinus surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alr.23220","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T02:04:25Z","timestamp":1687831465000},"page":"5-17","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real\u2010world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery"],"prefix":"10.1002","volume":"14","author":[{"given":"Jared","family":"Silver","sequence":"first","affiliation":[{"name":"GSK Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijita","family":"Deb","sequence":"additional","affiliation":[{"name":"GSK Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[{"name":"Groupe d'analyse Lt\u00e9e Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Gao","sequence":"additional","affiliation":[{"name":"Analysis Group Inc Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja18.00196"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci7040053"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004294"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2012.26.3762"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00043305"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13048"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21182"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.600"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020167"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22369"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22779"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753466618808490"},{"key":"e_1_2_9_14_1","unstructured":"EMA.Mepolizumab summary of product characteristics. Accessed August 2022 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/nucala\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_15_1","unstructured":"FDA.Mepolizumab prescribing information. Accessed August 2022 https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA\u2010PI\u2010PIL\u2010IFU\u2010COMBINED.PDF"},{"key":"e_1_2_9_16_1","unstructured":"GSK.Mepolizumab prescribing information Japan. Accessed August 2022 https:\/\/gskpro.com\/ja\u2010jp\/products\u2010info\/nucala\/index\/"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(12)60988\u2010X"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931\u2010021\u201001746\u20104"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.002"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1415"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.05.001"},{"key":"e_1_2_9_24_1","unstructured":"45 CFR Part 46 (2018\u201007\u201319). Accessed 26 January 2023.https:\/\/www.ecfr.gov\/on\/2018\u201007\u201319\/title\u201045\/subtitle\u2010A\/subchapter\u2010A\/part\u201046"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)75867-8"},{"key":"e_1_2_9_26_1","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J","year":"1988"},{"key":"e_1_2_9_27_1","article-title":"The Impact of Comorbid nasal polyps on real\u2010world mepolizumab effectiveness in patients with severe asthma: results from the REALITI\u2010A study","volume":"205","author":"Liu MC","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/17534666211009398"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3906\/sag\u20101912\u201362"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200906\u20100896OC"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.063"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12071096"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04590\u20102020"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21674"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.10.007"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(21)00097\u20107"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.05.021"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2020.41.200043"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S275944"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.10.010"},{"key":"e_1_2_9_42_1","unstructured":"Global Initiative For Asthma (GINA).Global Strategy for Asthma Management and Prevention. Accessed 26 January 2023.https:\/\/ginasthma.org\/gina\u2010reports\/"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21597"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2004.09.067"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.10.028"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010017\u20130571\u20138"}],"container-title":["International Forum of Allergy &amp; Rhinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alr.23220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T11:16:32Z","timestamp":1716376592000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/alr.23220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/alr.23220"],"URL":"https:\/\/doi.org\/10.1002\/alr.23220","archive":["Portico"],"relation":{},"ISSN":["2042-6976","2042-6984"],"issn-type":[{"value":"2042-6976","type":"print"},{"value":"2042-6984","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"2022-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}